American journal of therapeutics最新文献

{"title":"A Systematic Review and Meta-Analysis of Nivolumab Plus Ipilimumab for the Treatment of Microsatellite Instability-High Metastatic Colorectal Cancer-An LTE.","authors":"Faiza Fatima, Hammad Javaid, Umaima Cheema, Fatima Aslam, Maria Qadri, Ali Tahir Khan, Mavra, Iqra Shahid, Shamikha Cheema, Zaheer Qureshi","doi":"10.1097/MJT.0000000000002030","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002030","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Unintentional Therapeutic Errors in Health Care System in Nigeria.","authors":"Gideon S Alex, Nenubari Naabiae, Fortune C Orish, Uchenna Okafor, Chinedu Okoye, Babatunde Oyelana, Kene Eruchalu, Munir Elelu, Ekanem Nseabasi, Faith Eromon, Olubunmi Aribeana, Talatu Kassim, Hasiya Daura, Orish Ebere Orisakwe","doi":"10.1097/MJT.0000000000001917","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001917","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144673757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and Efficacy of Telemedicine for Patients With Advanced Cancer in the Outpatient Setting: Lessons Learned From a Pilot Trial.","authors":"Alexandra Kovacs, Estera Boeriu, Daniela Moşoiu","doi":"10.1097/MJT.0000000000002018","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002018","url":null,"abstract":"<p><strong>Background: </strong>Telemedicine (TM) was studied, particularly during the COVID-19 pandemic, to ascertain its utility in delivering remote medical services.</p><p><strong>Study question: </strong>What palliative care (PC) interventions can be provided through TM consultations compared with face-to-face (FF) consultations? What is their efficacy in reducing the intensity of suffering in the physical, emotional, social, and spiritual domains? What is the level of satisfaction with the care given?</p><p><strong>Study design: </strong>Randomized controlled trial with 2 arms: TM consultations using Zoom and WhatsApp secure platforms (Intervention group) and FF consultations (Control group). Participants received 8 scheduled weekly consultations and on-demand consultations.</p><p><strong>Measures and outcomes: </strong>The patients completed weekly Edmonton Symptom Assessment System, Problems and Needs in Palliative Care Short Form, and Patient Satisfaction Questionnaire Short Form monthly questionnaires. Statistical analyses were performed using GraphPad Prism 10.0.2.</p><p><strong>Results: </strong>Between July 2023 and January 2024, 26 patients with newly diagnosed advanced cancer were randomized, 23 completed the study and 3 died in the TM arm (attrition rate 11.53%). Enrolled participants had predominantly advanced head and neck cancer (30.76%) and digestive tract cancer (23.07%). Patients in the TM arm had a lower performance status compared with the FF group. One thousand one hundred sixty-eight PC interventions were performed, 628 (FF) versus 540 (TM). In the physical domain, 343 versus 266; in the emotional domain, 219 versus 206; in the social domain, 18 versus 18; in the spiritual domain, 48 versus 50. Higher reductions in symptom intensity scores were reported in the TM arm (100% for depression, anxiety, hemorrhage, dysphagia, and secretions; >90% for pain, nausea, and appetite; >80% for sleep, dyspnea, and constipation; and >70% for cough), with statistical significance for pain (P = 0.0140), nausea (P = 0.0148), depression (P = 0.0318), and constipation (P = 0.0100). High satisfaction scores (>80, range 18-90) were reported for both arms.</p><p><strong>Conclusions: </strong>This exploratory pilot study shows that TM PC interventions are feasible and lead to high reductions in intensity scores for symptoms, with high satisfaction scores.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144658160","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Megadose or High-dose Meropenem?","authors":"Parinaz Sadat Mahmoudi, Hossein Khalili","doi":"10.1097/MJT.0000000000001879","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001879","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Is Including a Carbapenem in Treatment Regimens for Infections Caused by Multidrug-Resistant Gram-Negative Pathogens Still Reasonable?","authors":"Fatemeh-Sadat Hosseini, Zahra Sharifi, Hossein Khalili","doi":"10.1097/MJT.0000000000001980","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001980","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641512","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Amphotericin B for Vascular Catheter-Associated Fungal Infections: Guidelines for Pharmacy Practice.","authors":"Parinaz Sadat Mahmoudi, Hossein Khalili","doi":"10.1097/MJT.0000000000001902","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001902","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144641511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Aprocitentan: The First Endothelin Receptor Antagonist for Resistant Hypertension.","authors":"Timothy Nguyen, Hui Lin, Diana Tint, Lorena Dima, Zhe Amy Wang","doi":"10.1097/MJT.0000000000001950","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001950","url":null,"abstract":"<p><strong>Background: </strong>Hypertension is a serious health problem, and resistant hypertension occurs when blood pressure (BP) is uncontrolled despite at least 3 optimal-dosed agents of different pharmacologic classes. Aprocitentan is a novel pharmacological agent approved in early 2024 for treatment of hypertension, in patients whom BP is not adequately controlled while on other antihypertensive medications.</p><p><strong>Mechanism of action, pharmacodynamics and pharmacokinetics: </strong>Aprocitentan acts as a dual endothelin receptor antagonist, inhibiting both ETa and ETb. It is postulated that low-renin models and salt-sensitive models of hypertension, consistent with resistant hypertension, exhibit increased levels of plasma ET-1. Thus, inhibition of ET-1 at ETa receptors inhibits vasoconstriction effects. The oral bioavailability of aprocitentan is currently unknown. Maximum plasma concentrations reaching a Cmax is within 4-5 hours with an effective half-life of 41 hours. Plasma concentrations increase in a dose-proportional manner and reach steady state within 8 days. The volume of distribution is 20 L, highly protein bound, primarily to albumin, and undergoes both renal and hepatic metabolism via UGT1A1- and UGT2B7-mediated N-glycosylation and nonenzymatic hydrolysis.</p><p><strong>Clinical trials: </strong>In a phase 3, multicenter-study in adult patients (N = 730) with systolic blood pressure ≥140 mm Hg with a run-in placebo and standard background BP therapy continued throughout the study, placebo or aprocitentan (12.5, 25 mg) were randomized at various stages. Aprocitentan 12.5 mg was superior to placebo in reducing sitting (sitting systolic blood pressure) at week 4, and a persistence of the BP-lowering effect was demonstrated (sitting systolic blood pressure was maintained and was statistically superior at week 40) when aprocitentan 25 mg were rerandomized to placebo.</p><p><strong>Therapeutic advance: </strong>Aprocitentan is a novel endothelin receptor antagonist approved for the treatment of resistant hypertension. It is a welcome development in the arsenal to fight against resistant hypertension for those with difficulty to manage with conventionally available antihypertensive medications.</p>","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144607178","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post-Furosemide Urinary Creatinine Excretion in Advanced Heart Failure.","authors":"Andrew Xanthopoulos, Charalambos Christofidis, Dimitrios E Magouliotis, Christos Kourek, Nikolaos Katsiadas, Thanos Athanasiou, Grigorios Giamouzis, Filippos Triposkiadis, Ioannis Stefanidis, John Skoularigis, Alexandros Briasoulis","doi":"10.1097/MJT.0000000000002005","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002005","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144599169","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Edoxaban Monotherapy Versus Dual Antithrombotic Therapy in Atrial Fibrillation With Stable Coronary Artery Disease: A Meta-Analysis of EPIC-CAD and PRAEDO-AF Trials.","authors":"Sufyan Shahid, Mohammad Hamza Bin Abdul Malik, Hasiba Karimi, Fazia Khattak, Anfal Hamza, Muhammad Arham, Muhammad Abdullah Ali","doi":"10.1097/MJT.0000000000002007","DOIUrl":"https://doi.org/10.1097/MJT.0000000000002007","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144537788","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Broad High-Trapping Glutamatergic Modulators in Treatment-Resistant Depression: Delving a Bit Into the Composite Mode of Action.","authors":"Ahmed Naguy, Hend F M F R Alenezi, Bibi Alamiri","doi":"10.1097/MJT.0000000000001997","DOIUrl":"https://doi.org/10.1097/MJT.0000000000001997","url":null,"abstract":"","PeriodicalId":7760,"journal":{"name":"American journal of therapeutics","volume":" ","pages":""},"PeriodicalIF":2.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526075","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}